U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns

The latest edition of Pharmalittle covers a range of developments in the pharmaceutical and biotech sectors, including U.S. pressure on Germany over drug pricing, concerns about FDA restructuring, and shifts in clinical trial strategies.

U.S. Pushes Germany to Increase Drug Payments

During a recent breakfast meeting, U.S. officials delivered a clear message to the German ambassador: increase payments for pharmaceuticals, according to STAT. The discussion involved U.S. Trade Representative Jamieson Greer, chief health department adviser Chris Klomp, and German Ambassador Jens Hanefeld.

The meeting was part of a broader effort by the Trump administration to encourage other countries to pay higher prices for medications, as the U.S. currently pays less. Officials raised the possibility of imposing tariffs under Section 301, which allows the government to address trade practices deemed “unfair.” While the German ambassador agreed to review the proposal with domestic officials, no agreement was reached.

Biotech Firms Rethink Clinical Trial Strategies Amid FDA Changes

Some U.S. biotech companies are exploring the relocation of early-stage clinical trials outside the United States due to concerns over layoffs and policy shifts at the FDA under the Trump administration, Reuters reports. The restructuring of the agency, including mass layoffs and leadership changes, has prompted smaller biotech firms to reconsider traditional pathways for drug development.

According to interviews with seven biotech executives, investors, and consultants, the changes at the FDA have led some companies to consider conducting trials in international markets such as the European Union and Australia. These firms are also seeking earlier engagement with regulators in these regions to streamline the drug development process.